These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 15495440)

  • 1. Prostate cancer: a review of common underwriting problems, Part 1.
    Richie RC; Swanson JO
    J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
    Nutahara K; Higashihara E
    Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen in clinical practice.
    Loeb S; Catalona WJ
    Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of screening for prostate cancer: a nested case-control study.
    Concato J; Wells CK; Horwitz RI; Penson D; Fincke G; Berlowitz DR; Froehlich G; Blake D; Vickers MA; Gehr GA; Raheb NH; Sullivan G; Peduzzi P
    Arch Intern Med; 2006 Jan; 166(1):38-43. PubMed ID: 16401808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of prostate cancer detected by digital rectal examination only.
    Okotie OT; Roehl KA; Han M; Loeb S; Gashti SN; Catalona WJ
    Urology; 2007 Dec; 70(6):1117-20. PubMed ID: 18158030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on screening for prostate cancer with prostate-specific antigen.
    Schmid HP; Riesen W; Prikler L
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):71-8. PubMed ID: 15094160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM; Hamilton RJ; Robertson CN; Butts MC; Freedland SJ
    Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case for prostate cancer screening.
    Andriole GL
    Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen testing and prostate cancer screening.
    Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
    Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.